Cancer Cachexia Market Size
Cancer Cachexia Market Size was valued at USD 2.45 Billion in 2024 and is expected to reach USD 3.6 Billion by 2034, growing at a CAGR of 4.3%
Cachexia is a complex metabolic syndrome characterized by severe and gradual weight loss caused mainly by skeletal muscle and adipose tissue depletion. This syndrome is more common in patients with advanced cancer, particularly those originating in the pancreas, lung, or gastrointestinal system. Cachexia differs from simple hunger or anorexia in that it includes a specific interplay between the tumor, the host's immune system, and multiple metabolic pathways. A significant metabolic change distinguishes cancer cachexia. Resting energy expenditure increases, contributing to the negative energy balance seen in cancer cachexia patients. Cancer cachexia impairs the body's normal response to reduced food intake, which is typically characterized by low CO2 generation. This means that despite inadequate nutritional intake, the body burns calories rapidly. The diagnosis uses criteria such as weight loss, body mass index, and decreased muscle strength. Cachexia increasingly becomes resistant to reversal as the illness progresses. Therefore, early diagnosis is critical. Treatment options are multifaceted and may include dietary support, exercise programs, and pharmaceutical medications that address inflammation and hypophagia. Cancer cachexia is one of the worst illnesses that a cancer patient can acquire, yet it is a complex clinical syndrome that can be treated effectively. Currently, research is focused on creating targeted therapies that can treat the underlying metabolic and inflammatory mechanisms that cause this disease. Understanding and effectively treating cancer-related cachexia is critical for improving cancer patients' quality of life, treatment outcomes, and overall survival.